On 2017 Feb 04, Stuart RAY commented:

Ribavirin monotherapy has been studied (summarized in Brok J, 2006), with no beneficial effect detected (an ACP Journal Club commentary was entitled, "ribavirin is not better than placebo" Chen W, 2006). This suggests that if the subset with high IFN-gamma was included in those trials, they did not benefit from ribavirin monotherapy. The comment's author may have conflated interferon gamma (a type II interferon) with interferon alfa (a type I interferon), the latter being a treatment that was enhanced by ribavirin.

On 2017 Feb 03, Muhammad Aslam commented:

In my view the patients with high IFNg plasma levels could benefit with Ribavirin only without suplementing with peginterferon.

On 2017 Feb 03, Muhammad Aslam commented:

In my view the patients with high IFNg plasma levels could benefit with Ribavirin only without suplementing with peginterferon.